Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoSeven

- PMLiVE

Novo Nordisk to acquire cardiovascular disease specialist Cardior in deal worth over €1bn

The deal includes a candidate being evaluated in a mid-stage trial to treat heart failure patients

- PMLiVE

Novo Nordisk’s Awiqli receives CHMP recommendation to treat diabetes in adults

The chronic disease is estimated to affect 415 million people worldwide

- PMLiVE

King’s College London and 11 London collaborate on health psychology

We’re delighted to announce that we are working in partnership with the Health Psychology department at King's College London. Professor Rona Moss-Morris is working with the agency on a shared...

11 London

- PMLiVE

Novo Nordisk shares promising phase 3 data for semaglutide in diabetes and chronic kidney disease

An estimated 40% of people living with type 1 or type 2 diabetes will develop CKD in their lifetime

- PMLiVE

Novo Nordisk and Neomorph enter molecular glue degrader partnership worth over $1.4bn

The companies will work on therapies for cardiometabolic and rare diseases

- PMLiVE

Almirall gains rights to Novo Nordisk’s IL-21 blocker for dermatological diseases

NN-8828 has been developed up to phase 2 in non-dermatological indications

Healthcare professionals seek independent medical education (IME)

The evolving healthcare advertising landscape

Industry experts share their insights on the emerging trends in healthcare advertising

Wiley

Matt Hunt

How we’re making AI a part of life at 11 London

This article talks about how AI is being used more in advertising, showing how it can change the way things are done from planning out strategies to coming up with...

11 London

- PMLiVE

Novo Nordisk announces two new research collaborations for cardiometabolic diseases

The research programmes will develop novel treatments for obesity and MASH

- PMLiVE

Novo Nordisk’s once-weekly IcoSema shows promise in phase 3a type 2 diabetes trial

IcoSema showed non-inferiority to daily insulin treatment in reducing blood glucose levels

- PMLiVE

Novo Nordisk announces $2.3bn investment to expand production site in France

The investment will increase the manufacturing capacity for Novo's GLP-1 products

- PMLiVE

Novo Nordisk to buy KBP’s hypertension drug ocedurenone for up to $1.3bn

An estimated 1.28 billion adults aged 30 to 79 years worldwide have hypertension

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links